Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update

Inhibrx, Inc. (NASDAQ:INBX) saw a significant drop in short interest in January. As of January 31st, there was short interest totalling 1,220,000 shares, a drop of 5.4% from the January 15th total of 1,290,000 shares. Approximately 12.3% of the company’s shares are short sold. Based on an average daily volume of 86,400 shares, the days-to-cover ratio is presently 14.1 days.

Inhibrx Price Performance

Shares of NASDAQ INBX opened at $13.07 on Wednesday. The company’s fifty day moving average is $13.98 and its 200-day moving average is $14.57. Inhibrx has a twelve month low of $10.80 and a twelve month high of $18.95.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reissued a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Institutional Investors Weigh In On Inhibrx

Several institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. bought a new stake in Inhibrx in the 4th quarter valued at $28,000. Natixis bought a new stake in Inhibrx during the 4th quarter worth about $31,000. JPMorgan Chase & Co. lifted its position in Inhibrx by 47.8% during the 4th quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company’s stock worth $117,000 after buying an additional 2,457 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Inhibrx during the 4th quarter worth about $47,000. Finally, New York State Common Retirement Fund bought a new stake in Inhibrx during the 4th quarter worth about $53,000. 82.46% of the stock is owned by institutional investors.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.